Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb 28:13:75.
doi: 10.1186/1475-2875-13-75.

Mefloquine safety and tolerability in pregnancy: a systematic literature review

Raquel González  1 , Urban Hellgren, Brian Greenwood, Clara Menéndez
Affiliations

Mefloquine safety and tolerability in pregnancy: a systematic literature review

Raquel González et al. Malar J. .

Abstract

Background: Control of malaria in pregnant women is still a major challenge as it constitutes an important cause of maternal and neonatal mortality. Mefloquine (MQ) has been used for malaria chemoprophylaxis in non-immune travellers for several decades and it constitutes a potential candidate for intermittent preventive treatment in pregnant women (IPTp).

Methods: The safety of MQ, including its safety in pregnancy, is controversial and a continuing subject of debate. Published studies which evaluated the use of MQ for malaria prevention or treatment in pregnant women and which reported data on drug tolerability and/or pregnancy outcomes have been reviewed systematically.

Results: Eighteen articles fitted the inclusion criteria, only one study was double-blind and placebo controlled. No differences were found in the risk of adverse pregnancy outcomes in women exposed to MQ compared to those exposed to other anti-malarials or to the general population. MQ combined with artesunate seems to be better tolerated than standard quinine therapy for treatment of non-severe falciparum malaria, but a MQ loading dose (10 mg/kg) is associated with more dizziness compared with placebo. When used for IPTp, MQ (15 mg/kg) may have more side effects than sulphadoxine- pyrimethamine.

Conclusions: In the published literature there are no indications that MQ use during pregnancy carries an increased risk for the foetus. Ideally, the use of MQ to prevent malaria should be based on a risk-benefit analysis of adverse effects against the risk of acquiring the infection. For this purpose double-blinded randomized controlled trials in African pregnant women are much needed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Diagram flow of articles selected.
See this image and copyright information in PMC

References

    1. Granja ACMF, Bergstrom S. Avoidability of maternal death in Mozambique: audit and retrospective risk assessment in 106 consecutive cases. Afr J Health Sci. 2000;7:83–87. - PubMed
    1. Menendez C, Bardaji A, Sigauque B, Romagosa C, Sanz S, Serra-Casas E, Macete E, Berenguera A, David C, Dobano C, Naniche D, Mayor A, Ordi J, Mandomando I, Aponte JJ, Mabunda S, Alonso PL. A randomized placebo-controlled trial of intermittent preventive treatment in pregnant women in the context of insecticide treated nets delivered through the antenatal clinic. PLoS One. 2008;3:e1934. doi: 10.1371/journal.pone.0001934. - DOI - PMC - PubMed
    1. Brabin BJ. An analysis of malaria in pregnancy in Africa. Bull World Health Organ. 1983;61:1005–1016. - PMC - PubMed
    1. Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, Newman RD. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis. 2007;7:93–104. doi: 10.1016/S1473-3099(07)70021-X. - DOI - PubMed
    1. Greenwood BM GA, Snow RW, Byass P, Bennett S, Hatib N`Jie AB. The effects of malaria chemoprophylaxis given by traditional birth attendantes on the course and outcome of pregnancy. Trans R Soc Trop Med Hyg. 1989;83:589–594. doi: 10.1016/0035-9203(89)90362-3. - DOI - PubMed

Publication types

MeSH terms